Clinical Trial

A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to assess the long-term safety and tolerability of LY4256984 in participants with Amyotrophic Lateral Sclerosis (ALS). This study is a long-term extension of study J6I-MC-OWAA (NCT07100119) and is part of the OLMP (NCT07571200) master protocol that will last approximately 96 weeks.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-06-25
notable Trial sites expanded: 3 -> 9 locations 2026-06-25
Trial Details
NCT Number NCT07571174
Lead Sponsor Eli Lilly and Company
Conditions Amyotrophic Lateral Sclerosis
Enrollment 32 participants
Start Date 2026-05-14
Primary Completion 2029-06 (estimated)
Study Completion 2029-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-17